Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.
Amneal Pharmaceuticals LLC is buying fellow generics drug maker Impax Laboratories Inc in an all-stock deal as a bulwark against a tough drug pricing environment.
Eli Lilly and Co said its recently approved breast cancer drug failed to meet a late-stage trial's main goal of improving overall survival in patients with non-small cell lung cancer.
Express Scripts Holding Co said on Tuesday it would buy privately held specialty healthcare benefits manager eviCore healthcare for $3.6 billion to bolster its medical benefits management business amid the threat of losing a major client.
Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular trading on Friday.
Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.
RedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower.
The U.S. Food and Drug Administration said it approved Abbott Laboratories' glucose monitoring device for adults with diabetes, allowing millions of people to track their blood sugar levels without having to prick their fingers.
Drug developer Axovant Sciences Ltd said it would stop testing its lead drug in Alzheimer's after it failed to meet the main goals of a late-stage trial, underlining the challenges in developing treatments for the memory-robbing disease.
Intellipharmaceutics International Inc, said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its opioid painkiller in its current form, asking for more proof of the drug's ability to prevent abuse.
- Gold: PRECIOUS-Gold falls as hopes of U.S. tax reform boost riskier assets
- Oil Report: Ecuador defends big Yasuni rainforest oil bet
- British Pound Report: Sterling bounces back, boosted by progress in Brexit talks
- US Dollar Report: FOREX-Dollar rises vs safe havens after U.S. Senate clears way for tax reform